La. Jury Hits J&J With $258M Verdict In Risperdal Suit

Law360, New York (October 15, 2010, 2:58 PM ET) -- A Louisiana jury has smacked a Johnson & Johnson unit with a $257.7 million verdict in the state's suit against the company for downplaying the link between its antipsychotic drug Risperdal and diabetes.

The jury reached a verdict late Thursday in the 27th Judicial Court, St. Landry Parish, finding that J&J and its unit Janssen Pharmaceutica Inc. made misrepresentations in 2003 and 2004 about the drug's link to diabetes, according to Louisiana Attorney General James D. “Buddy” Caldwell.

“This verdict sends a loud message to those...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required